Clinical trials
Kwashiorkor trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
45 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2006 | 1 |
| 2008 | 1 |
| 2009 | 3 |
| 2011 | 3 |
| 2013 | 2 |
| 2014 | 3 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 4 |
| 2021 | 6 |
| 2022 | 3 |
| 2023 | 5 |
| 2024 | 5 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 32 |
| Unknown status | 7 |
| Not yet recruiting | 2 |
| Recruiting | 2 |
| Active, not recruiting | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Washington University School of Medicine | 6 |
| University Ghent | 3 |
| Baylor College of Medicine | 2 |
| Maastricht University Medical Center | 2 |
| University of California, San Francisco | 2 |
| University of Oxford | 2 |
| Academy of Nutrition and Dietetics | 1 |
| Ain Shams University | 1 |
| Alliance for International Medical Action | 1 |
| Aristotle University Of Thessaloniki | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Kwashiorkor | 45 |
| Malnutrition | 10 |
| Protein-Energy Malnutrition | 10 |
| Severe Acute Malnutrition | 8 |
| Sarcopenia | 6 |
| Cachexia | 5 |
| Frailty | 4 |
| Growth Disorders | 3 |
| Cognitive Dysfunction | 2 |
| Critical Illness | 2 |
Trials
Showing 26 to 45 of 45. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.